The latest price target for Century Therapeutics (NASDAQ:IPSC) was reported by Guggenheim on January 22, 2025. The analyst firm set a price target for $0.00 expecting IPSC to fall to within 12 months (a possible -100.00% downside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Century Therapeutics (NASDAQ:IPSC) was provided by Guggenheim, and Century Therapeutics reiterated their buy rating.

There is no last upgrade for Century Therapeutics

The last downgrade for Century Therapeutics Inc happened on August 28, 2023 when JP Morgan changed their price target from $28 to $5 for Century Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Century Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Century Therapeutics was filed on January 22, 2025 so you should expect the next rating to be made available sometime around January 22, 2026.

While ratings are subjective and will change, the latest Century Therapeutics (IPSC) rating was a reiterated with a price target of $0.00 to $0.00. The current price Century Therapeutics (IPSC) is trading at is $0.80, which is out of the analyst’s predicted range.